Novartis's Sandoz licenses proposed multiple sclerosis biosimilar

The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news